Pharming Group
This sponsor has funded 1 studies across 11 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 7375 | Ongoing | C1 inhibitor Treatment Registry to assess the Safety and Immunological Profile of Ruconest in the treatment of HAE Attacks (Ruconest Registry) | No | No |
PAS by Risk Management Plan (RMP) requirement
Pharming Group
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Pharming Group
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Pharming Group
11 Study countries specified are the following:
- Bulgaria
- Croatia
- France
- Germany
- Hungary
- Italy
- Norway
- Poland
- Slovakia
- Slovenia
- Sweden